ANI PHARMACEUTICALS, INC Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation
ANI PHARMACEUTICALS, INC (ANIP) reported Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation of $617.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2019-02-27.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation · last filed 2019-02-27
- ANI PHARMACEUTICALS, INC adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2016 was $617.00K, a 71.39% increase from fiscal 2015.
- ANI PHARMACEUTICALS, INC adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2015 was $360.00K, a 54.08% decline from fiscal 2014.
- ANI PHARMACEUTICALS, INC adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2014 was $784.00K.
- ANI PHARMACEUTICALS, INC adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2013 was $0.00.
| Period end | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 12 month |
|---|---|
| 2016-12-31 | $617.00K 10-K · filed 2019-02-27 |
| 2015-12-31 | $360.00K 10-K · filed 2018-02-27 |
| 2014-12-31 | $784.00K 10-K · filed 2017-03-02 |
| 2013-12-31 | $0.00 10-K · filed 2016-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |